España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Prelude Therapeutics
PRLD
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$1.20
-0.00950
-0.79%
Pre-Market: 7:34 PM EDT
Get Report
Comment
Prelude Therapeutics (PRLD) Forecast
News
Earnings
Prelude Therapeutics (PRLD) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Prelude Therapeutics (NASDAQ:PRLD) Stock
Prelude Therapeutics Stock (NASDAQ: PRLD)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, December 11, 2024
JMP Securities Reiterates Market Outperform o...
Benzinga Newsdesk
Prelude Therapeutics Announced The Presentati...
Benzinga Newsdesk
Friday, November 08, 2024
HC Wainwright & Co. Reiterates Buy on Prelude...
Benzinga Newsdesk
Wednesday, November 06, 2024
Prelude Therapeutics Q3 EPS $(0.43) Beats $(0...
Benzinga Newsdesk
Monday, October 28, 2024
HC Wainwright & Co. Reiterates Buy on Prelude...
Benzinga Newsdesk
Wednesday, October 09, 2024
Prelude Therapeutics Announced The Publicatio...
Benzinga Newsdesk
Thursday, September 19, 2024
HC Wainwright & Co. Upgrades Prelude Therapeu...
Benzinga Newsdesk
Monday, September 16, 2024
JMP Securities Reiterates Market Outperform o...
Benzinga Newsdesk
HC Wainwright & Co. Reiterates Neutral on Pre...
Benzinga Newsdesk
Friday, September 13, 2024
Prelude Therapeutics' SMARCA2 Degrader PRT378...
Benzinga Newsdesk
Tuesday, September 10, 2024
HC Wainwright & Co. Reiterates Neutral on Pre...
Benzinga Newsdesk
Thursday, August 15, 2024
HC Wainwright & Co. Reiterates Neutral on Pre...
Benzinga Newsdesk
Wednesday, August 14, 2024
UBS Posts Upbeat Earnings, Joins Victoria's Secret, Performance Food Group, Kellanova And Other Big Stocks Moving Higher On Wednesday
Avi Kapoor
Monday, August 12, 2024
Prelude Therapeutics Q2 2024 GAAP EPS $(0.46)...
Benzinga Newsdesk
Tuesday, July 09, 2024
Prelude Therapeutics Collaborates With Merck ...
Benzinga Newsdesk
Wednesday, April 10, 2024
Prelude Therapeutics Disclosed Laurent Chardo...
Benzinga Newsdesk
Wednesday, March 13, 2024
JMP Securities Initiates Coverage On Prelude ...
Benzinga Newsdesk
Tuesday, February 20, 2024
HC Wainwright & Co. Downgrades Prelude Therap...
Benzinga Newsdesk
Friday, February 16, 2024
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights
Prelude Therapeutics shares are trading highe...
Benzinga Newsdesk
Thursday, February 15, 2024
Prelude Therapeutics Reports FY23 Financial R...
Benzinga Newsdesk
Tuesday, December 19, 2023
Morgan Stanley Downgrades Prelude Therapeutics: Here's What You Need To Know
Benzinga Insights
Morgan Stanley Downgrades Prelude Therapeutic...
Benzinga Newsdesk
Monday, December 11, 2023
Prelude Therapeutics Entered Into A Securitie...
Benzinga Newsdesk
Tuesday, November 07, 2023
HC Wainwright & Co. Maintains Buy on Prelude ...
Benzinga Newsdesk
Wednesday, November 01, 2023
Prelude Therapeutics Q3 EPS $(0.45) Beats $(0...
Benzinga Newsdesk
Prelude Therapeutics And AbCellera Enter Part...
Benzinga Newsdesk
Thursday, October 19, 2023
Best Buy To Rally More Than 21%? Here Are 10 Top Analyst Forecasts For Thursday
Lisa Levin
The Latest Analyst Ratings for Prelude Therapeutics
Benzinga Insights
HC Wainwright & Co. Maintains Buy on Prelude ...
Benzinga Newsdesk
Tuesday, October 10, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
Friday, September 15, 2023
Stocks That Hit 52-Week Lows On Friday
Benzinga Insights
Wednesday, August 23, 2023
Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights
Tuesday, August 22, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
Thursday, August 17, 2023
HC Wainwright & Co. Reiterates Buy on Prelude...
Benzinga Newsdesk
Friday, August 04, 2023
Morgan Stanley Reiterates Equal-Weight on Pre...
Benzinga Newsdesk
Barclays Maintains Equal-Weight on Prelude Th...
Benzinga Newsdesk
Thursday, August 03, 2023
Prelude Therapeutics Q2 EPS $(0.54) Beats $(0...
Benzinga Newsdesk
Wednesday, August 02, 2023
Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights
Monday, July 31, 2023
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
Friday, July 28, 2023
Stocks That Hit 52-Week Lows On Friday
Benzinga Insights
Thursday, July 27, 2023
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
Thursday, June 22, 2023
Board Member at Prelude Therapeutics Acquires Company Stock Options Worth 47,000 Shares
Benzinga Insights
Thursday, May 25, 2023
5.00M Reasons To Be Bullish On Prelude Therapeutics Stock
Benzinga Insights
Prelude Therapeutics Insider Trades Send a Signal
Benzinga Insights
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights
Thursday, May 18, 2023
Prelude Therapeutics shares are trading lower...
Benzinga Newsdesk
Prelude Therapeutics Reports Pricing Of Publi...
Benzinga Newsdesk
Wednesday, May 17, 2023
Prelude Therapeutics Reports Launch Of Propos...
Benzinga Newsdesk
Monday, May 08, 2023
Prelude Therapeutics Q1 EPS $(0.58) Beats $(0.68) Estimate
Happy Mohamed
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch
